Semaglutide vs. Revisional Surgery: Best for Weight Regain After Bariatric Procedures?

Primary bariatric surgery is highly effective for obesity and related comorbidities, but a significant challenge is recurrent weight gain in a subset of patients. This regain can lead to a return of metabolic complications and diminished quality of life. While revisional bariatric surgery has been a traditional intervention, the emergence of highly effective GLP-1 receptor agonists like semaglutide offers a new medical management option. This study directly compares the efficacy of revisional metabolic and bariatric surgery against semaglutide for managing recurrent weight gain after initial bariatric procedures.

Patients undergoing revisional bariatric surgery achieved significantly greater total body weight loss (TBWL) compared to those treated with semaglutide. At 24 months, the surgery group demonstrated a mean TBWL of 28.5% from their baseline weight, while the semaglutide group achieved a mean TBWL of 15.2% (p<0.001). > Revisional bariatric surgery demonstrated a superior mean total body weight loss of 28.5% at 24 months, significantly outperforming semaglutide's 15.2% TBWL (p<0.001). Furthermore, type 2 diabetes remission rates were substantially higher in the surgery group at 65% compared to 38% in the semaglutide group (p<0.01). Resolution of hypertension was also more frequent after surgery, observed in 55% of patients versus 30% with semaglutide (p<0.05). The overall adverse event rate was 12% for surgery (mostly minor complications) and 8% for semaglutide (primarily gastrointestinal side effects).